Prescriptions of GLP-1 drugs to children under 12 are rising at extraordinary speed. Are we turning a childhood health crisis into a lifetime pharmaceutical market?
Listen to the audio version of this article:
THE TOPLINE
- A national study found that 20,282 US children ages 8–11 with obesity but not diabetes received a GLP-1 prescription between 2019 and June 2026—a 310-fold increase.
- Wegovy’s safety and effectiveness for weight reduction have not been established in children under 12, and its adolescent evidence rests largely on one 68-week trial.
- New pancreatitis and vision warnings, together with surging FDA adverse-event reports, reinforce the need for stronger long-term surveillance.
The GLP-1 boom is moving into the elementary-school years.
A new Pediatrics study examined more than 3.5 million children ages 8–11 with obesity but not diabetes. Researchers found that 20,282 received prescriptions for drugs such as Saxenda, Wegovy, and Zepbound between 2019 and June 2026, representing 310-fold increase.
Use remained uncommon overall—about 0.6 percent—and nearly 94 percent of recipients had severe obesity. These children are not simply seeking a cosmetic shortcut. They face a genuine health crisis and deserve a pathway to good health.
But recognizing the problem does not require accepting the pharmaceutical industry’s preferred answer: placing ever-younger children on drugs that may need to be continued indefinitely while the conditions making them sick remain largely untouched.
Prescribing Is Racing Ahead of the Evidence
GLP-1 drugs can produce substantial weight loss and improve metabolic markers. For some high-risk patients, the benefits may be significant. The concern is the widening gap between adoption and long-term safety evidence.
Wegovy’s current US label states that safety and effectiveness for weight reduction have not been established below age 12. Its approval for those over the age of 12 rests largely on a 68-week trial of just 201 patients—hardly conclusive evidence against the possibility of exposure lasting decades.
Adverse effects were also common. In the trial, 62 percent of treated adolescents reported gastrointestinal reactions, compared with 42 percent receiving placebo. Nausea affected 42 percent and vomiting 36 percent. More than half experienced a maximum heart-rate increase of at least 20 beats per minute.
New Safety Warnings
And regulators continue to identify new risks. In January 2026, the UK medicines regulator strengthened class-wide pancreatitis warnings after receiving 1,296 reports, including 24 cases of necrotizing pancreatitis and 19 fatal reports.
Vision concerns have also arisen. The European Medicines Agency concluded that non-arteritic anterior ischemic optic neuropathy, or NAION—a condition that can cause sudden vision loss—is a very rare side effect of semaglutide. In July 2026, Australia added class-wide warnings for this potentially blinding condition.
Preliminary research presented at the 2026 American Academy of Orthopaedic Surgeons found that, at five years, GLP-1 users had higher recorded rates of osteoporosis and gout. This was an observational conference study, so more research is needed to confirm this concerning safety signal.
What we see in the news tells a different story of side effects. We hear about an ever-expanding list of the benefits of GLP-1 agonists. They improve heart health, protect your kidney, liver, and joints, give you better sleep, boost brain health—and maybe even slow aging.
Nearly 300,000 FDA Cases
But there is a story to be told about the harmful effects of these drugs.
At ANH-USA, we reviewed the FDA adverse-event database for semaglutide, tirzepatide, and liraglutide. The search returned 295,785 cases. Annual reports rose fifteen-fold between 2021 and 2025, from 5,451 to 82,419. Nearly 82 percent were received from 2023 onward, and gastrointestinal disorders appeared in roughly one-third.
These reports do not prove causation or reveal how frequently adverse events occur. The FDA warns that its system includes duplicate, incomplete, and unverified reports, while rising drug use also drives reporting. But the steep increase still demands stronger surveillance and better age-specific data—particularly when these drugs are moving toward younger patients.
A Lifetime-Treatment Model
GLP-1 drugs suppress appetite and slow gastric emptying while they are taken; they do not repair the food environment or build lasting metabolic resilience. A 2025 meta-analysis found significant weight regain beginning eight weeks after anti-obesity drugs were discontinued.
That creates a dependency problem: a prescription in childhood can become an implicit proposal for years or decades of treatment.
These drugs may have a role for selected high-risk patients, but they cannot substitute for prevention. America cannot inject its way out of a broken food system, sedentary living, and collapsing metabolic health. The 310-fold prescribing increase is a warning—not about the children, but about the direction of our healthcare system.
People taking a GLP-1 medicine should not stop or change treatment without consulting a qualified healthcare professional.
Please share this article widely in your networks.
